Role of folliculin (FLCN) in lung cell survival

滤泡素 (FLCN) 在肺细胞存活中的作用

基本信息

  • 批准号:
    8620705
  • 负责人:
  • 金额:
    $ 44.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2016-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cystic airspace enlargement and spontaneous pneumothorax are major pathological manifestations Birt-Hogg- Dube (BHD) syndrome. Although the etiology of this disease is not known, lung cysts in BHD are linked to autosomal dominant mutational inactivation of tumor suppressor gene folliculin (FLCN). FLCN, a 64-kDa ubiquitously expressed protein with high homology throughout species that lacks apparent functional domain, through adaptor proteins FNIP1/2, binds the 5'-AMP-activated protein kinase (AMPK). Little, however, is known about a role of folliculin (FLCN) in lung cell survival. Our in vitro and in vivo studies demonstrate that FLCN is required for lung cell survival by acting within 5'-AMP-activated protein kinase (AMPK) - tuberous sclerosis complex 2 (TSC2) - mammalian target of rapamycin complex 2 (mTORC2) signaling pathway. To fill a gap in the current understanding of airspace enlargement, we have restricted the scope of this proposal to one testable, central hypothesis that FLCN is required for lung cell survival. To test our hypothesis, in Aim 1, we will determine whether FLCN is required for lung epithelial cell survival in vivo using new transgenic FLCNf/f:SP-C- Cre mice generated in PI's lab. Targeted conditional inducible deletion of FLCN in SP-C-expressing lung epithelial cells will allow us to identify the specific lung epithelial cell type affected by FLCN loss that promotes alveolar space enlargement. In Aim 2 we will examine whether FLCN is required for maintenance of epithelial cell morphology and metabolism. In Aim 3, we will determine FLCN role in regulating activities of Akt and AMPK kinases, and whether pharmacological activation of AMPK will rescue lung epithelial cell survival with targeted inducible deletion of FLCN in FLCNf/f:SP-C-Cre mice. These studies will identify the role of FLCN in lung cell survival, provide insights into the cellular an molecular mechanism of lung epithelial cell-cell contacts, actin cytoskeleton, and metabolism regulated by FLCN. These studies will also establish a mechanistic link between loss of FLCN and cystic airspace enlargement by using our unique novel FLCNf/f:SP- C-Cre transgenic mice and identify potential molecular target(s) for novel therapeutic approaches to treat BHD.
描述(申请人提供):囊性空域扩大和自发性气胸是BHD综合征的主要病理表现。虽然这种疾病的病因尚不清楚,但BHD的肺囊肿与肿瘤抑制基因滤泡蛋白(FLCN)的常染色体显性突变失活有关。FLCN是一种64 kda的蛋白,在缺乏明显功能域的物种中普遍表达,具有高度同源性,通过衔接蛋白FNIP1/2结合5'- amp活化蛋白激酶(AMPK)。然而,对于滤泡蛋白(FLCN)在肺细胞存活中的作用所知甚少。我们的体外和体内研究表明,FLCN是肺细胞存活所必需的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VERA P KRYMSKAYA其他文献

VERA P KRYMSKAYA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VERA P KRYMSKAYA', 18)}}的其他基金

Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
治疗和预防肺淋巴管平滑肌瘤病 (LAM) 和结节性硬化症 (TSC) 的新型联合疗法
  • 批准号:
    10697901
  • 财政年份:
    2023
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTORC1 and WNT in lung mesenchyme
肺间质中的 mTORC1 和 WNT
  • 批准号:
    10278071
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTORC1 and WNT in lung mesenchyme
肺间质中的 mTORC1 和 WNT
  • 批准号:
    10435544
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis
硝唑尼特作为罕见疾病淋巴管平滑肌瘤病和结节性硬化症的新疗法
  • 批准号:
    10258194
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTORC1 and WNT in lung mesenchyme
肺间质中的 mTORC1 和 WNT
  • 批准号:
    10634760
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
  • 批准号:
    10163904
  • 财政年份:
    2020
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
  • 批准号:
    10394731
  • 财政年份:
    2020
  • 资助金额:
    $ 44.69万
  • 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
  • 批准号:
    10609457
  • 财政年份:
    2020
  • 资助金额:
    $ 44.69万
  • 项目类别:
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)
尿激酶型纤溶酶原激活剂 (uPA) 在淋巴管平滑肌瘤病 (LAM) 发病机制中的作用
  • 批准号:
    10323035
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)
肺淋巴管平滑肌瘤病 (LAM) 中的淋巴管生成
  • 批准号:
    9242060
  • 财政年份:
    2016
  • 资助金额:
    $ 44.69万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 44.69万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了